Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
Molecular Weight | 718.8 g/mol |
---|---|
Molecular Formula | C40H38N4O7S |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 5 |
Exact Mass | 718.24612074 g/mol |
Monoisotopic Mass | 718.24612074 g/mol |
Topological Polar Surface Area | 172 A^2 |
Heavy Atom Count | 52 |
Formal Charge | 0 |
Complexity | 1110 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Zyprexa relprevv |
Active Ingredient | Olanzapine pamoate |
Dosage Form | Suspension, extended release |
Route | Intramuscular |
Strength | eq 300mg base/vial; eq 210mg base/vial; eq 405mg base/vial |
Market Status | Prescription |
Company | Eli Lilly |
2 of 2 | |
---|---|
Drug Name | Zyprexa relprevv |
Active Ingredient | Olanzapine pamoate |
Dosage Form | Suspension, extended release |
Route | Intramuscular |
Strength | eq 300mg base/vial; eq 210mg base/vial; eq 405mg base/vial |
Market Status | Prescription |
Company | Eli Lilly |
RLD : Yes
TE Code :
Brand Name : ZYPREXA RELPREVV
Dosage Form : SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Dosage Strength : EQ 210MG BASE/VIAL
Approval Date : 2009-12-11
Application Number : 22173
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : ZYPREXA RELPREVV
Dosage Form : SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Dosage Strength : EQ 300MG BASE/VIAL
Approval Date : 2009-12-11
Application Number : 22173
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : ZYPREXA RELPREVV
Dosage Form : SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Dosage Strength : EQ 405MG BASE/VIAL
Approval Date : 2009-12-11
Application Number : 22173
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Regulatory Info :
Registration Country : Sweden
Brand Name : ZYPADHERA
Dosage Form : POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
Dosage Strength : 300 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : ZYPADHERA
Dosage Form : POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
Dosage Strength : 405 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : ZYPADHERA
Dosage Form : POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
Dosage Strength : 210 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Market Place
ABOUT THIS PAGE
A Olanzapine Pamoate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Olanzapine Pamoate, including repackagers and relabelers. The FDA regulates Olanzapine Pamoate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Olanzapine Pamoate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Olanzapine Pamoate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Olanzapine Pamoate supplier is an individual or a company that provides Olanzapine Pamoate active pharmaceutical ingredient (API) or Olanzapine Pamoate finished formulations upon request. The Olanzapine Pamoate suppliers may include Olanzapine Pamoate API manufacturers, exporters, distributors and traders.
click here to find a list of Olanzapine Pamoate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Olanzapine Pamoate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Olanzapine Pamoate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Olanzapine Pamoate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Olanzapine Pamoate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Olanzapine Pamoate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Olanzapine Pamoate suppliers with NDC on PharmaCompass.
Olanzapine Pamoate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Olanzapine Pamoate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Olanzapine Pamoate GMP manufacturer or Olanzapine Pamoate GMP API supplier for your needs.
A Olanzapine Pamoate CoA (Certificate of Analysis) is a formal document that attests to Olanzapine Pamoate's compliance with Olanzapine Pamoate specifications and serves as a tool for batch-level quality control.
Olanzapine Pamoate CoA mostly includes findings from lab analyses of a specific batch. For each Olanzapine Pamoate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Olanzapine Pamoate may be tested according to a variety of international standards, such as European Pharmacopoeia (Olanzapine Pamoate EP), Olanzapine Pamoate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Olanzapine Pamoate USP).
LOOKING FOR A SUPPLIER?